Eli Lilly and Company Stock Santiago S.E.

Equities

LLY

US5324571083

Pharmaceuticals

End-of-day quote Santiago S.E. 06:00:00 2024-07-04 pm EDT 5-day change 1st Jan Change
904.9 USD 0.00% Intraday chart for Eli Lilly and Company 0.00% 0.00%
Sales 2024 * 42.97B Sales 2025 * 52.69B Capitalization 827B
Net income 2024 * 11.93B Net income 2025 * 16.63B EV / Sales 2024 * 19.7 x
Net Debt 2024 * 19.94B Net Debt 2025 * 16.06B EV / Sales 2025 * 16 x
P/E ratio 2024 *
68.6 x
P/E ratio 2025 *
49.1 x
Employees 43,000
Yield 2024 *
0.57%
Yield 2025 *
0.65%
Free-Float 99.8%
More Fundamentals * Assessed data
Dynamic Chart
1 week
904.90
Extreme 904.9
904.90
1 month
904.90
Extreme 904.9
904.90
Current year
904.90
Extreme 904.9
904.90
1 year
904.90
Extreme 904.9
904.90
3 years
904.90
Extreme 904.9
904.90
5 years
904.90
Extreme 904.9
904.90
10 years
904.90
Extreme 904.9
904.90
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 95-12-31
President - -
Chief Tech/Sci/R&D Officer - 23-10-15
Members of the board TitleAgeSince
Director/Board Member 63 21-01-24
Director/Board Member 68 09-03-31
Director/Board Member 64 04-12-31
More insiders
Date Price Change Volume

End-of-day quote Santiago S.E., July 04, 2024

More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
918 USD
Average target price
870.3 USD
Spread / Average Target
-5.20%
Consensus